C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 201—LabelingSubpart A—General Labeling Provisions

21 C.F.R. § 201.5 (2026)

Drugs; adequate directions for use

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1978–2024 31citing cases
At a glance

Courts have cited this section in 31 opinions since 1978, 3 of them in the last five years.

Adequate directions for use means directions under which the layman can use a drug safely and for the purposes for which it is intended. (Section 201.128 defines “intended use.”) Directions for use may be inadequate because, among other reasons, of omission, in whole or in part, or incorrect specification of:

(a) Statements of all conditions, purposes, or uses for which such drug is intended, including conditions, purposes, or uses for which it is prescribed, recommended, or suggested in its oral, written, printed, or graphic advertising, and conditions, purposes, or uses for which the drug is commonly used; except that such statements shall not refer to conditions, uses, or purposes for which the drug can be safely used only under the supervision of a practitioner licensed by law and for which it is advertised solely to such practitioner.

(b) Quantity of dose, including usual quantities for each of the uses for which it is intended and usual quantities for persons of different ages and different physical conditions.

(c) Frequency of administration or application.

(d) Duration of administration or application.

(e) Time of administration or application (in relation to time of meals, time of onset of symptoms, or other time factors).

(f) Route or method of administration or application.

(g) Preparation for use, i.e., shaking, dilution, adjustment of temperature, or, other manipulation or process.

[41 FR 6908, Feb. 13, 1976]
The 20 cases that cite 21 C.F.R. § 201.5 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
cites § 201.5 8×cited by 77 cases
Where it cites § 201.5
“See 21 C.F.R. § 201.5 . Off-label promotional statements could thus presumably constitute evidence of an intended use of a drug that the FDA has not approved.”
The case’s holding
The First Amendment prohibits the government from criminalizing the truthful, non-misleading promotion of an FDA-approved drug for off-label use.
Later courts cite it for
“once fda-approved, prescription drugs can be prescribed by doctors for both fda-approved and -unapproved uses; the fda generally does not regulate how physicians use approved drugs.” · 4 citing courts
2
GREENFDA v. All. for Hippocratic Med., 602 U.S. 367 (2024).
cites § 201.5 1×cited by 260 cases
Where it cites § 201.5
“21 CFR §§ 201.5 , 314.50 (2022). If FDA determines that additional safety requirements are necessary, FDA may impose extra requirements on pre- scription and use of the drug.”
The case’s holding
Plaintiffs seeking injunctive relief must demonstrate an injury in fact, causation, and redressability to establish Article III standing.
Later courts cite it for
“a plaintiff must demonstrate (i) that she has suffered or likely will suffer an injury in fact, (ii) that the injury likely was caused or will be caused by the defendant, and (iii) that the injury likely would be redressed by the requested judicial relief.” · 65 citing courts
3
GREENUnited States v. Articles of Drug, 625 F.2d 665 (5th Cir. 1980).
cites § 201.5 4×cited by 15 cases
Where it cites § 201.5
“21 C.F.R. § 201.5 (1980). The Government states that not only has this been its interpretation for the twenty-eight years since the regulation was published, but that the regulation merely codified agency practice since 1938.”
4
GREENUnited States ex rel. Polansky v. Pfizer, Inc., 822 F.3d 613 (2d Cir. 2016).
cites § 201.5 1×cited by 21 cases
Later courts cite it for
“caronia left open the government's ability to prove misbranding on a theory that promotional speech provides evidence that a drug is intended for a use that is not included on the drug's fda- approved label.” · 2 citing courts
5
GREENUnited States v. Sene X Eleemosynary Corp., 479 F. Supp. 970 (S.D. Fla. 1979).
cites § 201.5 2×cited by 21 cases
Where it cites § 201.5
“Photographs, established to be all of the labeling on the drum of procaine, show that there are no adequate directions for use, as defined in the applicable regulation, 21 CFR 201.5, on the bulk component (PX 305).”
6
GREENAmarin Pharma, Inc. v. United States Food & Drug Admin., 119 F. Supp. 3d 196 (S.D.N.Y. 2015).
cites § 201.5 2×cited by 7 cases
Where it cites § 201.5
“” 21 C.F.R. § 201.5 . It has defined “intended use” as “the objective intent of the persons legally responsible for the labeling of drugs”; “intended use” may be demonstrated by “oral or written statements by such persons or their representatives” and “the circumstances that the…”
7
GREENIn re Avandia Mktg. Sales Practices & Prods. Liab. Litig., 588 F. App'x 171 (3d Cir. 2014).
cites § 201.5 1×cited by 19 casesunpublished
Where it cites § 201.5
“§ 355; 21 C.F.R. § 201.5 . 20 . See Conn. Gen.Stat.”
Later courts cite it for
“refused to find the words 'safe and effective' to create an express warranty in the absence of representations that a drug was free from all harmful side effects or was absolutely harmless” · 9 citing courts
8
GREENIn re Trasylol Prods. Liab. Litig., 709 F. Supp. 2d 1323 (S.D. Fla. 2010).
cites § 201.5 1×cited by 18 cases
Where it cites § 201.5
“§ 352 and 21 CFR § 201.5 in Opinion # 2, the section “Bases of Opinions #1 & #2” does not analyze Bayer’s actions under the cited statute and regulation but rather provides a general background on the FDA process and the role of the FDA.”
Later courts cite it for
“generally takes a collection of facts, imputes motive and knowledge, and draws unsupported conclusions unrelated to any regulatory expertise.” · 1 citing court
9
GREENSpectrum Pharm., Inc v. Sylvia Burwell, 824 F.3d 1062 (D.C. Cir. 2016).
cites § 201.5 1×cited by 7 cases
Where it cites § 201.5
“2014) (recognizing that to satisfy the statutory requirement that a drug’s label provide “ ‘adequate directions for use,’ a drug’s label must provide ‘directions under which the layman can use a drug safely and for the purposes for which it is intended’ ” (quoting 21 C.F.R. §…”
Later courts cite it for
“designed to treat a rare disease or condition that historically received little attention from pharmaceutical companies.” · 2 citing courts
10
GREENUnited States v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014).
cites § 201.5 1×cited by 15 cases
Where it cites § 201.5
“” 21 C.F.R. § 201.5 (emphasis added). A prescription drug, however, is by definition “not safe for use except under the supervision of a practitioner licensed by law to administer such drug.”
Later courts cite it for
“would be unnecessary if the fdca did not otherwise regulate the distribution of drugs by licensed physicians.” · 1 citing court
11
GREENUnited States v. H. Ray Evers, M. D., 643 F.2d 1043 (5th Cir. 1981).
cites § 201.5 1×cited by 31 cases
Where it cites § 201.5
“That interpretation begins with 21 C.F.R. § 201.5 (1980), which defines “adequate directions for use” as “directions under which the layman can use a drug safely and for the purposes for which it is intended.”
The case’s holding
A physician who distributes prescription drugs only to their own patients does not hold those drugs for sale under the misbranding statute.
Later courts cite it for
“while the fdca was not intended to regulate the practice of medicine, it was obviously intended to control the availability of drugs for prescribing by physicians.” · 5 citing courts
12
GREENFDA v. All. for Hippocratic Med., 602 U.S. 367 (2024).
cites § 201.5 1×cited by 34 cases
Where it cites § 201.5
“21 CFR §§201.5 , 314.50 (2022). If FDA determines that additional safety requirements are necessary, FDA may impose extra requirements on prescription and use of the drug.”
13
GREENUnited States v. Articles of Drug, 585 F.2d 575 (3d Cir. 1978).
cites § 201.5 1×cited by 22 cases
Where it cites § 201.5
“Adequate directions for use “means directions under which the layman can use a drug safely and for the purposes for which it is intended,” 21 C.F.R. § 201.5 (1977). In its complaint the Government argued that Lannett’s drugs, as prescription drugs, by their very nature could not…”
Later courts cite it for
“me-too' drugs carry the same qualities as generic drugs, irrespective of individual manufacturing differences, and therefore should be treated the same for purposes of the drug act.” · 2 citing courts
14
GREENUnited States v. US Stem Cell Clinic, LLC, 998 F.3d 1302 (11th Cir. 2021).
cites § 201.5 1×cited by 4 cases
Where it cites § 201.5
“§ 352 (f)(1); see 21 C.F.R. § 201.5 . In fact, the FDA argued, the Clinic could not label the stromal-vascular fraction solution in compliance with the FDCA because “there is no scientifically valid evidence to show that it is safe or effective for any indication.”
15
REDUnited States v. Caronia, 576 F. Supp. 2d 385 (E.D.N.Y. 2008).
cites § 201.5 1×cited by 8 cases
Vacated by United States v. Caronia (2012): the Court of Appeals for the Second Circuit's own opinion in this case.
Where it cites § 201.5
“” FDA regulations provide that “adequate directions for use” are directions "under which the layman can use a drug safely and for the purposes for which it is intended!,]” 21 C.F.R. § 201.5 , and further provide that a drug's “intended use” is determined by considering the…”
16
GREENUnited States v. Algon Chem. Inc., 879 F.2d 1154 (3d Cir. 1989).
cites § 201.5 1×cited by 15 cases
Where it cites § 201.5
“21 C.F.R. § 201.5 . In the present case, the labeling on the bulk drugs sold by Algon consisted merely of the name of the drug, the country of origin and numerical information such as the net weight of the contents, although some of the labeling also contained the following…”
Later courts cite it for
“the fda's action effecting an increase in cost of drugs to practitioners does not undermine the practice of medicine or treatment decisions of veterinarians.” · 1 citing court
17
GREENUnited States ex rel. Polansky v. Pfizer, Inc., 914 F. Supp. 2d 259 (E.D.N.Y. 2012).
cites § 201.5 1×cited by 7 cases
Where it cites § 201.5
“21 CFR § 201.5 . These directions must indicate the purposes for which the drug has been found to be both safe and effective.”
Later courts cite it for
“cannot accept plaintiff's theory that what scientists at the national cholesterol education program clearly intended to be advisory guidance is transformed into a legal restriction simply because the fda has determined to pass along that advice through the label.” · 2 citing courts
18
GREENUnited States v. Undetermined Quantities of Articles of Drug, 145 F. Supp. 2d 692 (D. Md. 2001).
cites § 201.5 1×cited by 6 cases
Where it cites § 201.5
“A product is misbranded if it fails to include adequate directions for use. See 21 U.S.C. § 352 (f)(1). “ ‘Adequate directions for use’ means directions under which the layman can use a drug safely and for the purposes for which it is intended.”
19
GREENAventis Pharm., Inc. v. Barr Labs., Inc., 411 F. Supp. 2d 490 (D.N.J. 2006).
cites § 201.5 1×cited by 6 cases
Where it cites § 201.5
“128 , which, in conjunction with 21 C.F.R. § 201.5 , requires adequate labeling for all intended uses of a drug, and expressly states: The words ‘intended uses’ .”
20
GREENUnited States v. Regenerative Sciences, LLC, 878 F. Supp. 2d 248 (D.D.C. 2012).
cites § 201.5 1×cited by 6 cases
Where it cites § 201.5
“” 21 C.F.R. § 201.5 . However, a prescription drug by its very definition cannot bear “adequate directions for use” by a layman.”
Later courts cite it for
“to constitute final agency action, two conditions must be met: (1) 'the action must mark the consummation of the agency's decisionmaking process' and (2) it 'must be one by which rights or obligations have been determined, or from which legal consequences will flow.” · 2 citing courts

Show all 31 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197820012024

One bar per year. Tallest: 3 cases in 2012. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
3rd Cir.32d Cir.25th Cir.26th Cir.2D.C. Cir.2D.D.C.2S.D. Fla.2E.D.N.Y2

The 8 courts with the most citing cases, of 20 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 31 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com